The FDA approved a subcutaneous formulation of the blockbuster cancer drug pembrolizumab (Keytruda Qlex) for use across the drug's numerous solid tumors indications. The new formulation combines ...

With biosimilar competition heading toward Keytruda, Merck & Co. last Tuesday launched a subcutaneous version of the flagship cancer medication that analysts believe will significantly offset a ...

A phase 2 trial evaluating CS-1103 in participants with methamphetamine use disorder is expected to begin in the first quarter of 2026. The Food and Drug Administration (FDA) has granted Fast Track ...

Danish biotechnology leader Genmab A/S (CSE: GMAB) is reportedly in advanced negotiations to acquire Merus NV (NASDAQ: MRUS), a Dutch biotech company specializing in innovative cancer therapies.

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — The Danish company Genmab said Monday it planned to buy Merus, ...

For people who rely on certain prescription drugs, including weight loss, asthma and cancer medications, President Donald Trump’s post announcing 100% tariffs on foreign brand-name drugs offers little ...

The Los Angeles Chargers apparently feel good enough about the running back depth chart to avoid any major roster moves or additions in the wake of the Najee Harris season-ending injury. Meaning, now ...

Today, a brief rundown of news involving Merck & Co. and MBX Biosciences, as well as updates from Roche, Sanofi and Ionis Pharmaceuticals that you may have missed. Roche on Monday said a regimen ...

Drugs included in the looming patent cliff include Merck’s cancer immunotherapy Keytruda, which made the firm just under $30 billion in sales last year. In 2028, Merck’s Keytruda patent will end, ...

ESMO 2025 will showcase over 20 late-breaking abstracts on genitourinary malignancies, emphasizing novel therapies and precision medicine. Key trials include AMPLITUDE on niraparib and abiraterone, ...

Merck & Co., Inc. (NYSE:MRK) is one of the 13 Best Fortune 500 Dividend Stocks to Invest In. Following a decline in revenue in the second quarter of 2025, the company received the FDA approval for ...